Johnson & Johnson $JNJ Shares Bought by Federated Hermes Inc.

Federated Hermes Inc. raised its holdings in Johnson & Johnson (NYSE:JNJ) by 24.6% during the 3rd quarter, Holdings Channel reports. The firm owned 3,446,111 shares of the company’s stock after buying an additional 679,872 shares during the quarter. Johnson & Johnson makes up about 1.1% of Federated Hermes Inc.’s holdings, making the stock its 8th largest holding. Federated Hermes Inc.’s holdings in Johnson & Johnson were worth $638,978,000 at the end of the most recent reporting period.

Other hedge funds and other institutional investors have also recently made changes to their positions in the company. Evolution Wealth Management Inc. acquired a new stake in shares of Johnson & Johnson in the second quarter valued at about $27,000. Clayton Financial Group LLC purchased a new position in Johnson & Johnson in the 3rd quarter valued at about $28,000. Semmax Financial Advisors Inc. boosted its holdings in Johnson & Johnson by 55.0% in the 2nd quarter. Semmax Financial Advisors Inc. now owns 203 shares of the company’s stock worth $31,000 after buying an additional 72 shares during the last quarter. GFG Capital LLC acquired a new position in shares of Johnson & Johnson during the second quarter valued at approximately $35,000. Finally, Signature Resources Capital Management LLC lifted its position in shares of Johnson & Johnson by 262.9% in the third quarter. Signature Resources Capital Management LLC now owns 254 shares of the company’s stock valued at $47,000 after acquiring an additional 184 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Trading Down 0.2%

Shares of Johnson & Johnson stock opened at $227.17 on Friday. The stock has a 50 day moving average of $210.25 and a 200 day moving average of $190.83. The company has a debt-to-equity ratio of 0.50, a quick ratio of 0.80 and a current ratio of 1.07. The firm has a market capitalization of $547.31 billion, a price-to-earnings ratio of 20.56, a PEG ratio of 2.21 and a beta of 0.34. Johnson & Johnson has a fifty-two week low of $141.50 and a fifty-two week high of $230.00.

Johnson & Johnson (NYSE:JNJ) last posted its earnings results on Wednesday, January 21st. The company reported $2.46 EPS for the quarter, meeting analysts’ consensus estimates of $2.46. The company had revenue of $24.56 billion for the quarter, compared to the consensus estimate of $24.14 billion. Johnson & Johnson had a return on equity of 33.34% and a net margin of 28.46%.The company’s revenue for the quarter was up 9.1% on a year-over-year basis. During the same quarter in the previous year, the business earned $2.04 earnings per share. Johnson & Johnson has set its FY 2026 guidance at 11.430-11.630 EPS. As a group, research analysts predict that Johnson & Johnson will post 10.58 earnings per share for the current year.

Johnson & Johnson Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, March 10th. Shareholders of record on Tuesday, February 24th will be given a dividend of $1.30 per share. The ex-dividend date is Tuesday, February 24th. This represents a $5.20 dividend on an annualized basis and a dividend yield of 2.3%. Johnson & Johnson’s dividend payout ratio (DPR) is currently 47.06%.

More Johnson & Johnson News

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Key legal risk reduced — a U.S. judge dismissed a lawsuit alleging J&J committed fraud by repeatedly trying to use a shell company’s bankruptcy to resolve talc claims, removing one potential overhang on the stock. US judge tosses lawsuit accusing J&J of fraud over talc bankruptcy strategy
• Positive Sentiment: Analyst bullishness and higher targets after Q4 — Scotiabank raised its JNJ price target to $265 (from $230) and reiterated an Outperform rating following the quarter, supporting upside expectations. Scotiabank Raises Johnson & Johnson Target
• Positive Sentiment: Fund and analyst endorsements reinforce momentum — coverage from Barron’s, Zacks and bullish analyst notes highlight J&J’s Q4 beat, solid guidance and growth drivers in Innovative Medicine and MedTech. These narratives help justify recent multiple expansion and investor interest. This Winning Fund Pro Likes J&J
• Neutral Sentiment: Unusually high options volume — trading flow shows elevated speculative or hedging activity, which can amplify short‑term volatility but doesn’t change fundamentals. Monitor open interest and put/call skew for directional cues. Johnson & Johnson Sees Unusually High Options Volume
• Negative Sentiment: Insider selling — CEO Joaquin Duato recently sold roughly $22M in JNJ stock days after the quarter, which can be perceived negatively by investors despite possible pre‑arranged sale plans; worth watching for follow‑up disclosures. CEO Dumps $22M in Stock Post Q4

Analysts Set New Price Targets

A number of brokerages have weighed in on JNJ. Citigroup raised their price objective on Johnson & Johnson from $232.00 to $250.00 and gave the company a “buy” rating in a report on Thursday, January 22nd. Argus boosted their price target on shares of Johnson & Johnson from $210.00 to $240.00 in a research report on Friday, January 23rd. Barclays upped their price objective on shares of Johnson & Johnson from $197.00 to $217.00 and gave the company an “equal weight” rating in a research note on Tuesday, December 30th. HSBC restated a “buy” rating and set a $240.00 target price on shares of Johnson & Johnson in a report on Wednesday, December 10th. Finally, UBS Group reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Monday, January 5th. One analyst has rated the stock with a Strong Buy rating, seventeen have given a Buy rating and eight have assigned a Hold rating to the stock. Based on data from MarketBeat.com, Johnson & Johnson has an average rating of “Moderate Buy” and an average price target of $230.36.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.